H.R. 7085 118th Congress
BIOSECURE Act
- Government Operations and Politics
- Sponsor: Rep. Gallagher, Mike [R-WI-8]
- Congress.gov ↗
Latest action, Jan 25, 2024: Referred to the House Committee on Oversight and Accountability.
How the Senate voted
The Senate hasn't taken a roll call on this bill in the Congresses covered.
10 cosponsors
Sponsored by Rep. Gallagher, Mike [R-WI-8] (Republican). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
6 D · 4 R
Referred to: House: Oversight and Government Reform Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
4 reports
4 reports
COMPLETE GENOMICS, INC.
AVOQ, LLC
4 reports
COMPLETE GENOMICS, INC.
CLS STRATEGIES (FORMERLY CHLOPAK, LEONARD, SCHECHTER AND ASSOCIATES, INC.)
4 reports
ILLUMINA, INC.
AVENUE SOLUTIONS
4 reports
4 reports
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
CROSSROADS STRATEGIES, LLC
4 reports
4 reports
4 reports
3 reports
GLAXOSMITHKLINE LLC
LMH STRATEGIC SOLUTIONS
3 reports
3 reports
3 reports
LONZA GROUP AG
CROWELL & MORING LLP
3 reports
All 25 of 36 clients
| Client | Lobbying firm | Reports | Reports totaling | From | To | Senate |
|---|---|---|---|---|---|---|
| AKEBIA THERAPEUTICS, INC. | 4 | $1.1M | Q1 2024 | Q3 2024 | yes | |
| ASTRAZENECA PHARMACEUTICALS LP | 4 | $2.9M | Q1 2024 | Q3 2024 | yes | |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 4 | $6.7M | Q1 2024 | Q3 2024 | yes | |
| COMPLETE GENOMICS, INC. | AVOQ, LLC | 4 | $580K | Q1 2024 | Q3 2024 | yes |
| COMPLETE GENOMICS, INC. | CLS STRATEGIES (FORMERLY CHLOPAK, LEONARD, SCHECHTER AND ASSOCIATES, INC.) | 4 | $600K | Q1 2024 | Q3 2024 | yes |
| ILLUMINA, INC. | AVENUE SOLUTIONS | 4 | $0 | Q1 2024 | Q3 2024 | yes |
| NEUROCRINE BIOSCIENCES, INC | 4 | $3.3M | Q1 2024 | Q3 2024 | yes | |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | CROSSROADS STRATEGIES, LLC | 4 | $0 | Q1 2024 | Q3 2024 | yes |
| TAKEDA PHARMACEUTICALS AMERICA INC | 4 | $2.9M | Q1 2024 | Q3 2024 | yes | |
| THERMO FISHER SCIENTIFIC INC | 4 | $1.9M | Q1 2024 | Q3 2024 | yes | |
| BATTELLE MEMORIAL INSTITUTE | 3 | $700K | Q4 2024 | Q3 2024 | yes | |
| GLAXOSMITHKLINE LLC | LMH STRATEGIC SOLUTIONS | 3 | $120K | Q4 2024 | Q3 2024 | yes |
| GSK (FKA GLAXOSMITHKLINE INC.) | 3 | $3.9M | Q1 2024 | Q3 2024 | yes | |
| IGM BIOSCIENCES, INC. | 3 | $240K | Q1 2024 | Q3 2024 | yes | |
| LONZA GROUP AG | CROWELL & MORING LLP | 3 | $60K | Q4 2024 | Q3 2024 | yes |
| PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC | COVINGTON & BURLING LLP | 3 | $0 | Q4 2024 | Q3 2024 | yes |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 3 | $23.4M | Q1 2024 | Q3 2024 | yes | |
| UNIVERSITY OF MICHIGAN | 3 | $190K | Q4 2024 | Q3 2024 | yes | |
| ACADIA PHARMACEUTICALS | 2 | $730K | Q4 2024 | Q3 2024 | yes | |
| EMD SERONO, INC. | THE MCMANUS GROUP | 2 | $0 | Q1 2024 | Q2 2024 | yes |
| IONIS PHARMACEUTICALS, INC. | 2 | $160K | Q4 2024 | Q3 2024 | yes | |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | AEGIS LLC | 2 | $0 | Q4 2024 | Q3 2024 | yes |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | THE MCMANUS GROUP | 2 | $0 | Q1 2024 | Q2 2024 | yes |
| VERTEX PHARMACEUTICALS INCORPORATED | 2 | $2.1M | Q1 2024 | Q2 2024 | yes | |
| WITH HONOR ACTION, INC. | 2 | $80K | Q1 2024 | Q2 2024 | yes |